- Home
- DXC vs ZYME Comparison
DXC vs ZYME Comparison
Compare DXC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXC | ZYME |
|---|---|---|
| Founded | 1959 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | DXC | ZYME |
|---|---|---|
| Price | $14.63 | $23.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $15.33 | ★ $32.75 |
| AVG Volume (30 Days) | ★ 1.6M | 925.5K |
| Earning Date | 01-29-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1492.90 | N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $12,714,000,000.00 | $134,481,000.00 |
| Revenue This Year | N/A | $64.28 |
| Revenue Next Year | N/A | $106.98 |
| P/E Ratio | $7.31 | ★ N/A |
| Revenue Growth | N/A | ★ 116.21 |
| 52 Week Low | $11.82 | $9.03 |
| 52 Week High | $23.75 | $28.49 |
Technical Indicators
Market Signals| Indicator | DXC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 42.36 |
| Support Level | $14.79 | $22.46 |
| Resistance Level | $15.59 | $24.80 |
| Average True Range (ATR) | 0.48 | 1.28 |
| MACD | -0.06 | -0.34 |
| Stochastic Oscillator | 41.18 | 22.48 |
Price Performance
Historical ComparisonAbout DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.